Uses
Prevention of Cardiovascular Events
Reduce the risk of MI or angina and the risk of undergoing revascularization procedures in patients without clinical evidence of CHD who have multiple risk factors (e.g., age, smoking, hypertension, low HDL-cholesterol concentrations, family history of early CHD).
Reduce the risk of MI or stroke in patients without clinical evidence of CHD who have type 2 diabetes mellitus and other risk factors (e.g., smoking, hypertension, retinopathy, microalbuminuria, macroalbuminuria).
Reduce the risk of nonfatal MI, fatal and nonfatal stroke, angina, or hospitalization for CHF, and the risk of undergoing revascularization procedures in patients with clinical evidence of CHD.
Has been used to slow the progression of coronary atherosclerosis† in patients with CHD.
Intensive antilipemic therapy (atorvastatin 80 mg daily) shown to be more effective than moderate antilipemic therapy (pravastatin 40 mg daily) in reducing the risk of cardiovascular events in patients hospitalized for acute coronary syndrome† (16% reduction in composite risk of death or major cardiovascular events for atorvastatin compared with pravastatin regimen). Intensive antilipemic therapy also more effective in slowing progression of coronary atherosclerosis† in patients with CHD.
Use fixed-combination preparation (Caduet®) when treatment with both atorvastatin and amlodipine is appropriate.
Dyslipidemias
Adjunct to dietary therapy in adults to decrease elevated serum total cholesterol, LDL-cholesterol, apolipoprotein B (apo B), and triglyceride concentrations, and to increase HDL-cholesterol concentrations in the management of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia and other causes of hypercholesterolemia (e.g., polygenic hypercholesterolemia). May be used in combination with ezetimibe for additive antilipemic effects.
Adjunct to dietary therapy to decrease elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in the management of heterozygous familial hypercholesterolemia in boys and postmenarchal girls ≥10 years of age who have a serum LDL-cholesterol concentration of ≥190 mg/dL and in those who have a serum LDL-cholesterol concentration of ≥160 mg/dL and either a family history of premature cardiovascular disease or multiple cardiovascular risk factors despite an adequate trial of dietary management.
Reduction of elevated serum total and LDL-cholesterol concentrations in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies (e.g., plasma LDL-apheresis) or when such therapies are not available. May be used in combination with ezetimibe for additive antilipemic effects.
Adjunct to dietary therapy for the treatment of patients with primary dysbetalipoproteinemia.
Adjunct to dietary therapy in the management of patients with elevated serum triglyceride concentrations.
Reduce total and LDL-cholesterol concentrations in patients with hypercholesterolemia associated with or exacerbated by renal transplantation† or use of protease inhibitors†.
Reduce total and LDL-cholesterol concentrations in hypercholesterolemic patients on peritoneal dialysis†.
Use fixed-combination preparation (Caduet®) when treatment with both atorvastatin and amlodipine is appropriate.
Print
Email
Save
Media Gallery
Drug Info Tools
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
